the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.
due to high recurrence rate of spontaneous bacterial peritonitis , we will study and evaluate the possible efficacy and safety of NTZ as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
60
nitazoxanide adjuvant to standard therapy
Standard therapy
Prevention of Secondary Spontaneous Bacterial Peritonitis
Reduction in incidence of secondary Spontaneous Bacterial Peritonitis (SBP) compared to control group
Time frame: 3 months
Change in Biological Biomarkers
Measurement of Tumor necrosis factor alfa , Procalcitonin(PCT), C-Reactive protein(CRP) and Erythrocyte sedimentation rate(ESR) with further calculation of PEC index \[PEC index = PCT × (ESR + CRP)\] before and after trial period
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.